Biogen & AbbVie’s Once-Monthly ZINBRYTA Approved in European Union

The European Commission (EC) has granted marketing authorization for ZINBRYTA (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen and AbbVie recently announced. ZINBRYTA is a once-monthly, self-administered, subcutaneous injection.

“Clinical data showed ZINBRYTA significantly reduced relapses, 24-week confirmed disability progression and new brain lesions for up to three years compared to AVONEX (interferon beta-1a) intramuscular injection, providing a valuable new option for people with RMS,” said Professor Gavin Giovannoni, Chair of Neurology, Blizard Institute, Barts and The London School of Medicine and Dentistry. “ZINBRYTA has an immunomodulatory mechanism of action (MOA) that regulates inflammation without broadly depleting the immune system, and immune cell effects are reversible within 6 months. This offers an alternative approach to treating multiple sclerosis (MS) and is an important consideration when deciding how to sequence therapies throughout the course of a patient’s disease.”

The EC approval of ZINBRYTA is supported by results from two studies, including DECIDE, the largest and longest head-to-head Phase III study ever conducted in MS. The Phase IIb SELECT and Phase III DECIDE studies were global, randomized, double-blind, controlled studies that involved approximately 2,400 people living with RMS. Some patients in DECIDE were treated for up to 3 years.

In DECIDE and SELECT, ZINBRYTA significantly reduced patients’ annualized relapse rate (ARR), the primary endpoint of the studies, by 45% compared to AVONEX up to 144 weeks and by 54% compared to placebo at 52 weeks (both p<0.0001), respectively. Analyses of these studies demonstrated the consistent effect of ZINBRYTA relative to placebo and AVONEX across various subgroups of patients defined by demographic and MS disease characteristics.

“With the approval of ZINBRYTA in the European Union, we are providing a much needed treatment option for people living with MS,” said Michael Severino, MD, Executive Vice President, Research and Development and Chief Scientific Officer, AbbVie. “This is an important part of AbbVie’s ongoing commitment to advancing neuroscience research specifically in the area of MS.”

In addition to the statistically significant ARR, the Summary of Product Characteristics (SmPC) also includes the following ZINBRYTA clinical measures:

-Statistically significant effect on 24-week confirmed disability progression in ZINBRYTA-treated patients with a hazard ratio of 0.73 [95% Confidence Interval 0.55, 0.98].
-Statistically significant reduction in the number of new or newly enlarging T2 hyperintense lesions, the number of new T1 Gd-enhancing lesions and the mean number of new T1 hypointense lesions at 96 weeks.
-Reduced clinically meaningful worsening in the patient-reported physical impact of MS (=7.5 point worsening from baseline to week 96 in the MSIS-29 physical score) compared to AVONEX.

“ZINBRYTA is an important new once-monthly option for people with RMS, including those whose disease activity has been insufficiently controlled by their prior therapy,” said Alfred Sandrock, MD, PhD, Executive Vice President and Chief Medical Officer at Biogen. “MS manifests differently in each person, with varied symptoms and progressions; therefore, it is important that people living with the disease have treatment choices to address their diverse and evolving needs.”

ZINBRYTA’s MOA is thought to block the activation of autoreactive T-cells, a major contributor to inflammation in the nervous system of people with MS. ZINBRYTA leads to an increase in immunoregulatory CD56bright natural killer (NK) cells, which have been shown to selectively decrease activated T-cells that contribute to the nerve injury caused by MS. These immunomodulatory effects of ZINBRYTA are believed to reduce central nervous system pathology in MS and thereby reduce the occurrence of relapse and disability progression.

-During ZINBRYTA treatment, mean cell counts for the major immune subsets (T, B, and NK cells) remained within normal ranges; total lymphocyte, T and B cell counts decreased on average =10% from baseline during the first year of treatment.
-Total lymphocyte counts returned to baseline within approximately eight to 12 weeks after the last dose, and all other cell counts studied returned to baseline within approximately 20 to 24 weeks after the last dose.

DECIDE was a 2- to 3-year, Phase III, global, randomized, double-blind, multicenter study in patients with relapsing forms of multiple sclerosis (RMS) designed to determine if ZINBRYTA would provide superior outcomes for certain clinical endpoints compared to treatment with AVONEX (interferon beta-1a) 30-mcg intramuscular (IM) injection. DECIDE was an active comparator study with two groups: 150 mg of subcutaneous ZINBRYTA every 4 weeks (n=919) was compared to AVONEX IM once weekly (n=922).

SELECT was a multicenter, randomized, double-blind, Phase IIb study that evaluated the efficacy and safety of ZINBRYTA 150 mg (n=208) and 300 mg (n=209) subcutaneous every 4 weeks for 1 year versus placebo (n=204) in patients with relapsing forms of multiple sclerosis (RMS).

ZINBRYTA is being developed globally for relapsing forms of multiple sclerosis (RMS). The recommended dosage of ZINBRYTA is 150 mg, self-administered subcutaneously on a monthly basis. ZINBRYTA is also approved in the United States and is under regulatory review in Switzerland, Canada and Australia.

In clinical trials, ZINBRYTA demonstrated superior efficacy in relapse reduction and MRI, key measures of MS disease activity, compared to AVONEX (interferon beta-1a) intramuscular injection and placebo. In the EU, an educational program to inform physicians and patients about the risk of severe hepatic injury and the procedures related to the appropriate management of this risk to minimize its occurrence and its severity.

ZINBRYTA is a humanized IgG1 monoclonal antibody that selectively binds to the high-affinity interleukin-2 (IL-2) receptor subunit (CD25). CD25 is expressed at high levels on T-cells that become activated in people with MS.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, visit www.biogen.com.

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For more information, visit www.abbvie.com.